Galmed Pharmaceuticals Ltd - Asset Resilience Ratio
Galmed Pharmaceuticals Ltd (GLMD) has an Asset Resilience Ratio of 45.65% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See GLMD working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2025)
This chart shows how Galmed Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Galmed Pharmaceuticals Ltd.
Liquid Assets Composition Over Time
This chart breaks down Galmed Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Galmed Pharmaceuticals Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.35 Million | 45.65% |
| Total Liquid Assets | $8.35 Million | 45.65% |
Asset Resilience Insights
- Very High Liquidity: Galmed Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 45.65% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Galmed Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Galmed Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Galmed Pharmaceuticals Ltd (2014–2025)
The table below shows the annual Asset Resilience Ratio data for Galmed Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 76.08% | $14.17 Million | $18.63 Million | +18.35pp |
| 2024-12-31 | 57.72% | $10.68 Million | $18.50 Million | -1.09pp |
| 2023-12-31 | 58.82% | $9.78 Million | $16.63 Million | -12.25pp |
| 2022-12-31 | 71.06% | $11.77 Million | $16.56 Million | -16.17pp |
| 2021-12-31 | 87.23% | $31.93 Million | $36.60 Million | +3.35pp |
| 2020-12-31 | 83.88% | $43.94 Million | $52.38 Million | +6.67pp |
| 2019-12-31 | 77.21% | $59.56 Million | $77.14 Million | +4.33pp |
| 2018-12-31 | 72.88% | $66.03 Million | $90.60 Million | +42.46pp |
| 2017-12-31 | 30.42% | $5.98 Million | $19.64 Million | -44.66pp |
| 2016-12-31 | 75.08% | $12.35 Million | $16.45 Million | -2.59pp |
| 2015-12-31 | 77.67% | $18.84 Million | $24.26 Million | +52.61pp |
| 2014-12-31 | 25.06% | $8.25 Million | $32.92 Million | -- |
About Galmed Pharmaceuticals Ltd
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have… Read more